Plitidepsin in patients with advanced renal cancer (RCC):: Results of an exploratory phase II trial

被引：0
|
作者：
Climent, Miguel A.
Schoffski, Patrick
Paz-Ares, Luis
Rivera, Fernando
Bezares, Susana
Pico, Cesar
Tabernero, Josep M.
机构：
[1] Inst Valenciano Oncol, Valencia, Spain
[2] Catholic Univ Leuven Hosp, Canc Inst, Louvain, Belgium
[3] Hosp Univ 12 Octubre, Madrid, Spain
[4] Hosp Univ Marques Vadecilla, Santander, Spain
[5] PharmaMar SAU, Madrid, Spain
[6] Hosp Gen Valle Hebron, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：147 / 147
页数：1
相关论文
共 50 条
  • [1] Plitidepsin in patients with advanced colorectal cancer (CRC): Results of an exploratory phase II trial
    Tabernero, Josep M.
    Rivera, Fernando
    Casado, Esther
    Sanchez, Antonio
    Bezares, Susana
    Pico, Cesar
    Paz-Ares, Luis
    ANNALS OF ONCOLOGY, 2006, 17 : 122 - 122
  • [2] Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure
    Tannir, N. M.
    Wong, Y.
    Kollmannsberger, C. K.
    Ernstoff, M. S.
    Perry, D. J.
    Appleman, L. J.
    Posadas, E. M.
    Qian, J.
    Ricker, J. L.
    Michaelson, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results
    Tannir, N.
    Wong, Y.
    Kollmannsberger, C.
    Ernstoff, M. S.
    Perry, D. J.
    Appleman, L. J.
    Posadas, E.
    Qian, J.
    Ricker, J. L.
    Michaelson, D. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Infliximab:: A phase II trial of the tumour necrosis factor (TNFα) monoclonal antibody in patients with advanced renal cell cancer (RCC).
    Maisey, NR
    Hall, K
    Lee, C
    Timotheadou, E
    Ahern, R
    Eisen, T
    Gore, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 385S - 385S
  • [5] Infliximab:: A phase II trial of the tumour necrosis factor (TNFα) monoclonal antibody in patients with advanced renal cell cancer (RCC)
    Maisey, NR
    Hall, K
    Lee, C
    Timotheadou, E
    Ahern, R
    Eisen, T
    Gore, M
    BRITISH JOURNAL OF CANCER, 2004, 91 : S21 - S21
  • [6] Final results of a Phase II randomised study of cediranib (RECENTIN™) in patients with advanced renal cell carcinoma (RCC)
    Mulders, P.
    Hawkins, R.
    Nathan, P.
    de Jong, I.
    Osanto, S.
    Porfiri, E.
    Protheroe, A.
    Mookerjee, B.
    Pike, L.
    Gore, M. E.
    EJC SUPPLEMENTS, 2009, 7 (03): : 21 - 21
  • [7] Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)
    Hainsworth, JD
    Sosman, JA
    Spigel, DR
    Schwert, RC
    Carrell, DL
    Hubbard, F
    Greco, FA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 382S - 382S
  • [8] Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients
    Merchan, J. R.
    Pitot, H. C.
    Qin, R.
    Liu, G.
    Fitch, T. R.
    Picus, J.
    Maples, W. J.
    Erlichman, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Preliminary report from an exploratory Phase II trial with Plitidepsin (Aplidin®) in patients with refractory/relapsed multiple myeloma.
    Mateos, MV
    Blade, J
    Prosper, F
    Lahuerta, JJ
    Garcia-Sanz, R
    Cibeira, M
    Rusiñol, L
    Escalante, F
    Ruiz, M
    Richardson, PG
    Miguel, JFS
    BLOOD, 2005, 106 (11) : 722A - 722A
  • [10] PHASE-II TRIAL OF VINBLASTINE PLUS NIFEDIPINE (VN) IN PATIENTS WITH ADVANCED RENAL-CELL CARCINOMA (RCC)
    SCHWARTSMANN, G
    DACUNHA, FM
    SILVEIRA, LA
    SALGADO, G
    THEREZA, MS
    VINHOLES, J
    PREGER, P
    SEGAL, F
    ANNALS OF ONCOLOGY, 1991, 2 (06) : 443 - 443
12345